{"title":"基于预测概率监测的贝叶斯单臂设计","authors":"Patrick D Mitchell","doi":"10.15406/bbij.2018.07.00222","DOIUrl":null,"url":null,"abstract":"Typically oncology programs begin development in humans using dose escalation trials with the purpose of determining the maximum tolerable dose. This or some lower dose is then tested in a series of trials in order to determine the anti-tumor potential of the drug along with other objectives such as mechanism of action. Following this determination, trials are usually conducted to establish the comparative efficacy of the experimental drug with an established treatment or standard of care.","PeriodicalId":90455,"journal":{"name":"Biometrics & biostatistics international journal","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"A Bayesian single-arm design using predictive probability monitoring\",\"authors\":\"Patrick D Mitchell\",\"doi\":\"10.15406/bbij.2018.07.00222\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Typically oncology programs begin development in humans using dose escalation trials with the purpose of determining the maximum tolerable dose. This or some lower dose is then tested in a series of trials in order to determine the anti-tumor potential of the drug along with other objectives such as mechanism of action. Following this determination, trials are usually conducted to establish the comparative efficacy of the experimental drug with an established treatment or standard of care.\",\"PeriodicalId\":90455,\"journal\":{\"name\":\"Biometrics & biostatistics international journal\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-07-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biometrics & biostatistics international journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15406/bbij.2018.07.00222\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biometrics & biostatistics international journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15406/bbij.2018.07.00222","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
A Bayesian single-arm design using predictive probability monitoring
Typically oncology programs begin development in humans using dose escalation trials with the purpose of determining the maximum tolerable dose. This or some lower dose is then tested in a series of trials in order to determine the anti-tumor potential of the drug along with other objectives such as mechanism of action. Following this determination, trials are usually conducted to establish the comparative efficacy of the experimental drug with an established treatment or standard of care.